Multi-year, multi-program research collaboration, option and license agreement addressing broad therapeutic area of cardiovascular diseases. The partnership will leverage Dewpoint’s proprietary platform for biomolecular condensates and Bayer’s small molecule compound library and R&D capabilities to identify and advance novel therapeutics.
Exclusive research collaboration to utilize Dewpoint’s proprietary platform for condensate biology to discover and develop therapies with a novel mechanism for the treatment of HIV.
Research collaboration that leverages Dewpoint’s technology platform to generate a condensate relevant, HTS amenable assay to screen Pfizer’s proprietary compound collection to identify compounds for the development of potential therapeutics for the treatment of myotonic dystrophy type 1, DM1, a rare genetic disorder and one of two types of myotonic dystrophy.
Research and development partnership to identify drug candidates using Dewpoint’s discovery platform related to biomolecular condensates to treat insulin resistance. The partnership brings together Novo Nordisk’s global leadership in treating diabetes and metabolic diseases with Dewpoint’s groundbreaking discovery and AI technology platform to identify modulators of biomolecular condensates.